Podoplanin is indispensable for cell motility and platelet-induced epithelial-to-mesenchymal transition-related gene expression in esophagus squamous carcinoma TE11A cells.
Crispr-Cas-9
Esophageal squamous cell carcinoma
Knockdown
Metastasis
Platelet
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
04
2020
accepted:
07
06
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
The transmembrane glycoprotein podoplanin (PDPN) is upregulated in some tumors and has gained attention as a malignant tumor biomarker. PDPN molecules have platelet aggregation-stimulating domains and, are therefore, suggested to play a role in tumor-induced platelet activation, which in turn triggers epithelial-to-mesenchymal transition (EMT) and enhances the invasive and metastatic activities of tumor cells. In addition, as forced PDPN expression itself can alter the propensity of certain tumor cells in favor of EMT and enhance their invasive ability, it is also considered to be involved in the cell signaling system. Nevertheless, underlying mechanisms of PDPN in tumor cell invasive ability as well as EMT induction, especially by platelets, are still not fully understood. Subclonal TE11A cells were isolated from the human esophageal squamous carcinoma cell line TE11 and the effects of anti-PDPN neutralizing antibody as well as PDPN gene knockout on platelet-induced EMT-related gene expression were measured. Also, the effects of PDPN deficiency on cellular invasive ability and motility were assessed. PDPN-null cells were able to provoke platelet aggregation, suggesting that PDPN contribution to platelet activation in these cells is marginal. Nevertheless, expression of platelet-induced EMT-related genes, including vimentin, was impaired by PDPN-neutralizing antibody as well as PDPN deficiency, while their effects on TGF-β-induced gene expression were marginal. Unexpectedly, PDPN gene ablation, at least in either allele, engendered spontaneous N-cadherin upregulation and claudin-1 downregulation. Despite these seemingly EMT-like alterations, PDPN deficiency impaired cellular motility and invasive ability even after TGF-β-induced EMT induction. These results suggested that, while PDPN seems to function in favor of maintaining the epithelial state of this cell line, it is indispensable for platelet-mediated induction of particular mesenchymal marker genes as well as the potentiation of motility and invasion capacity.
Sections du résumé
BACKGROUND
BACKGROUND
The transmembrane glycoprotein podoplanin (PDPN) is upregulated in some tumors and has gained attention as a malignant tumor biomarker. PDPN molecules have platelet aggregation-stimulating domains and, are therefore, suggested to play a role in tumor-induced platelet activation, which in turn triggers epithelial-to-mesenchymal transition (EMT) and enhances the invasive and metastatic activities of tumor cells. In addition, as forced PDPN expression itself can alter the propensity of certain tumor cells in favor of EMT and enhance their invasive ability, it is also considered to be involved in the cell signaling system. Nevertheless, underlying mechanisms of PDPN in tumor cell invasive ability as well as EMT induction, especially by platelets, are still not fully understood.
METHODS
METHODS
Subclonal TE11A cells were isolated from the human esophageal squamous carcinoma cell line TE11 and the effects of anti-PDPN neutralizing antibody as well as PDPN gene knockout on platelet-induced EMT-related gene expression were measured. Also, the effects of PDPN deficiency on cellular invasive ability and motility were assessed.
RESULTS
RESULTS
PDPN-null cells were able to provoke platelet aggregation, suggesting that PDPN contribution to platelet activation in these cells is marginal. Nevertheless, expression of platelet-induced EMT-related genes, including vimentin, was impaired by PDPN-neutralizing antibody as well as PDPN deficiency, while their effects on TGF-β-induced gene expression were marginal. Unexpectedly, PDPN gene ablation, at least in either allele, engendered spontaneous N-cadherin upregulation and claudin-1 downregulation. Despite these seemingly EMT-like alterations, PDPN deficiency impaired cellular motility and invasive ability even after TGF-β-induced EMT induction.
CONCLUSIONS
CONCLUSIONS
These results suggested that, while PDPN seems to function in favor of maintaining the epithelial state of this cell line, it is indispensable for platelet-mediated induction of particular mesenchymal marker genes as well as the potentiation of motility and invasion capacity.
Identifiants
pubmed: 32581653
doi: 10.1186/s12935-020-01328-2
pii: 1328
pmc: PMC7310449
doi:
Types de publication
Journal Article
Langues
eng
Pagination
263Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no conflict of interest.
Références
Sci Rep. 2017 Jul 28;7(1):6798
pubmed: 28754892
Cancer Res. 2001 Jan 1;61(1):376-82
pubmed: 11196190
Cancer Sci. 2013 Dec;104(12):1718-25
pubmed: 24103048
J Cell Sci. 2006 Nov 1;119(Pt 21):4541-53
pubmed: 17046996
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Cancer Sci. 2018 Dec;109(12):3671-3678
pubmed: 30238699
Biochem J. 2008 Apr 1;411(1):133-40
pubmed: 18215137
Cancer Metastasis Rev. 2019 Sep;38(3):483-492
pubmed: 31734763
J Biol Chem. 2013 Apr 26;288(17):12215-21
pubmed: 23530051
Sci Immunol. 2017 May 5;2(11):
pubmed: 28763790
Int J Mol Sci. 2019 Feb 06;20(3):
pubmed: 30736372
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1301-7
pubmed: 16979138
Cancer Cell. 2006 Apr;9(4):261-72
pubmed: 16616332
Nat Biotechnol. 2018 Sep;36(8):703-704
pubmed: 30059492
Mol Med Rep. 2015 Sep;12(3):4029-4036
pubmed: 26095281
Cancer Sci. 2008 Jan;99(1):54-61
pubmed: 17944973
Front Immunol. 2012 Sep 12;3:283
pubmed: 22988448
Int J Mol Sci. 2018 Apr 20;19(4):
pubmed: 29677116
Cancer Sci. 2012 Nov;103(11):1913-9
pubmed: 22816430
PLoS One. 2013 Aug 21;8(8):e73609
pubmed: 23991201
BMC Cancer. 2018 Oct 1;18(1):939
pubmed: 30285678
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
Blood Adv. 2018 Sep 11;2(17):2214-2225
pubmed: 30190281
Appl Immunohistochem Mol Morphol. 2014 May-Jun;22(5):331-47
pubmed: 23531849
Int J Oncol. 2016 Jun;48(6):2310-20
pubmed: 27035755
J Cell Sci. 2019 Feb 25;132(5):
pubmed: 30745334
Nature. 2013 Oct 3;502(7469):105-9
pubmed: 23995678
BMC Cancer. 2019 Jan 17;19(1):85
pubmed: 30654768
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Cancer Sci. 2018 May;109(5):1292-1299
pubmed: 29575529
Cancer Metastasis Rev. 2017 Jun;36(2):225-234
pubmed: 28674748
Oncotarget. 2016 Jan 26;7(4):3934-46
pubmed: 26684030
Cancer Sci. 2017 Apr;108(4):696-703
pubmed: 28182302
Sci Rep. 2017 Jun 22;7(1):4059
pubmed: 28642617
J Biol Chem. 2007 Sep 7;282(36):25993-6001
pubmed: 17616532
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Thromb Haemost. 2017 Mar;15(3):513-525
pubmed: 28028907
Cell Rep. 2018 Apr 17;23(3):808-822
pubmed: 29669286
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Mol Pharmacol. 2013 Jul;84(1):25-40
pubmed: 23580446
Sci Rep. 2017 Feb 08;7:42186
pubmed: 28176852
Ann Surg Oncol. 2010 May;17(5):1311-23
pubmed: 20066519